J&J reiterates 2025 sales goal despite looming Stelara exclusivity loss, global economic challenges

Johnson & Johnson is doubling down on a mid-decade pharma sales goal, and it’s plotting a way even as it loses exclusivity on one of its main blockbusters later this year.

Joaquin Duato — who became J&J’s CEO last year after Alex Gorsky stepped aside — repeated the company’s target for $60 billion in pharma sales revenue by 2025 in an investor call Tuesday morning.